These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7652488)

  • 21. A fluid future for liquid biopsies: Despite recent progress, most noninvasive cancer tests must still prove their mettle in the laboratory and the clinic.
    Nelson B
    Cancer Cytopathol; 2018 Dec; 126(12):963-964. PubMed ID: 30570835
    [No Abstract]   [Full Text] [Related]  

  • 22. Pharmacogenomic biomarkers for personalized cancer treatment.
    Rodríguez-Antona C; Taron M
    J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analytical requirements and standardization of CA 15-3.
    van Dalen A
    Scand J Clin Lab Invest Suppl; 1995; 221():102-4. PubMed ID: 7652484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Institutional prevalence of malignancy of indeterminate thyroid cytology is necessary but insufficient to accurately interpret molecular marker tests.
    Valderrabano P; Leon ME; Centeno BA; Otto KJ; Khazai L; McCaffrey JC; Russell JS; McIver B
    Eur J Endocrinol; 2016 May; 174(5):621-9. PubMed ID: 26903551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic test accuracy of nutritional tools used to identify undernutrition in patients with colorectal cancer: a systematic review.
    Håkonsen SJ; Pedersen PU; Bath-Hextall F; Kirkpatrick P
    JBI Database System Rev Implement Rep; 2015 May; 13(4):141-87. PubMed ID: 26447079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [What importance do tumor markers have in life insurance medicine?].
    Binsack T; Kraus HK
    Versicherungsmedizin; 1990 Dec; 42(6):157-62. PubMed ID: 2291265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Issues and barriers to development of clinically useful tumor markers: a development pathway proposal.
    Hammond ME; Taube SE
    Semin Oncol; 2002 Jun; 29(3):213-21. PubMed ID: 12063674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Use of Human Epididymis 4 and Cancer Antigen 125 Tumor Markers in the Benign or Malignant Differential Diagnosis of Pelvic or Adnexal Masses.
    Dolgun ZN; Kabaca C; Karateke A; İyibozkurt C; İnan C; Altıntaş AS; Karadağ C
    Balkan Med J; 2017 Apr; 34(2):156-162. PubMed ID: 28418343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of a New Survivin ELISA and UBC
    Gleichenhagen J; Arndt C; Casjens S; Meinig C; Gerullis H; Raiko I; Brüning T; Ecke T; Johnen G
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29324722
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for cervical cancer: new alternatives and research.
    Lörincz AT
    Salud Publica Mex; 2003; 45 Suppl 3():S376-87. PubMed ID: 14746031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The utility of serum receptor-binding cancer antigen expressed on SiSo cells in gastrointestinal tract cancers.
    Coban S; Ozkan H; Köklü S; Yüksel O; Koçkar MC; Akar T; Ormeci N
    Can J Gastroenterol; 2006 Sep; 20(9):593-6. PubMed ID: 17001401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.
    Seemann MD; Beinert T; Fürst H; Fink U
    Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
    Amacher DE
    Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is gene array testing to be considered routine now?
    Paik S
    Breast; 2011 Oct; 20 Suppl 3():S87-91. PubMed ID: 22015300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A tumour-marker combination versus second-look surgery in ovarian cancer. I. Clinical experience.
    Lahousen M; Stettner H; Pürstner P
    Baillieres Clin Obstet Gynaecol; 1989 Mar; 3(1):201-8. PubMed ID: 2661094
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.